Lung PD-L1

22C3 PharmDx28-8 PharmDxSP142 AssaySP263 Assay
Atezolizumab--

1L (≥50% TC or ≥10% IC), companion

-
Durvalumab---consolidation therapy, companion (≥1% TC)
Nivolumab----
Pembrolizumab1L (≥50% TPS) & 2L (≥1% TPS) companion--1L (≥50% TPS) & 2L (≥1% TPS) companion

Therapies

Stage III, unresectable NSCLC – consolidation therapy 
PD-L1 testing: companion - ≥1% TC

VENTANA PD-L1 (SP263) Assay

1st line and 2nd line advanced or metastatic NSCLC
PD-L1 testing: companion
     1st line: TPS ≥50%
     2nd line: TPS ≥1%

VENTANA PD-L1 (SP263) Assay

PD-L1 IHC 22C3 PharmDx